AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12960117 — intervention group
Group type: COMPARATOR
Intervention: Placebo once/day
Number of subjects: 40
Study 11115219 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 736
Study 11115219 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 736
Study 11115219 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg three times daily
Number of subjects: 736
Study 11115219 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg three times daily
Number of subjects: 736
Study 9039546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 382
Study 9039546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 9039546 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin + Ethambutol
Number of subjects: 382
Study 1394826 — intervention group
Group type: EXPERIMENTAL
Intervention: M-VAC therapy (methotrexate, vinblastine, adriamycin, and cisplatin)
Number of subjects: 86
Study 1394826 — intervention group
Group type: EXPERIMENTAL
Intervention: M-VAC therapy
Number of subjects: 86
Study 3871883 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 5 mg every 6 hours orally (n = 82)
Number of subjects: 164
Study 3871883 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 82)
Number of subjects: 164
Study 30416083 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg Q4W
Number of subjects: 1926
Study 30416083 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg Q8W
Number of subjects: 1926
Study 30416083 — intervention group
Group type: COMPARATOR
Intervention: Placebo (previous trials)
Number of subjects: 1926
Study 29996933 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised relaxation intervention practiced nightly for 4 weeks.
Number of subjects: 128
Study 29996933 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised relaxation intervention (active intervention).
Number of subjects: 128
Study 29996933 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 128
Study 27107010 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS) with superior turbinate biopsy
Number of subjects: 131
Study 27107010 — intervention group
Group type: COMPARATOR
Intervention: Functional endoscopic sinus surgery (FESS) only (control group)
Number of subjects: 131
Study 25048506 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided sedation with propofol and remifentanil
Number of subjects: 180
Study 25048506 — intervention group
Group type: COMPARATOR
Intervention: Control group monitored by the Modified Observer's Assessment of Alertness and Sedation scale
Number of subjects: 180
Study 22901973 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy for 6 months
Number of subjects: 86
Study 20116285 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid-enhanced MR imaging
Number of subjects: 36
Study 20116285 — intervention group
Group type: COMPARATOR
Intervention: Four-phase multi-detector row computed tomography (CT)
Number of subjects: 36
Study 17667568 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 111
Study 17667568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 111
Study 17667568 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 111
Study 17667568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 111
Study 17667568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 111
Study 17667568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 111
Study 17667568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 111
Study 16052045 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH 150 IU/day
Number of subjects: 63
Study 16052045 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH 225 IU/day
Number of subjects: 63
Study 11573752 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT) from dietitians using a NCEP based lowering protocol
Number of subjects: 90
Study 11573752 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) from physicians
Number of subjects: 90
Study 11573752 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 90
Study 11573752 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 90
Study 9758087 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (cand.cil.) 8 mg o.i.d. (increased to 16 mg o.i.d. if necessary)
Number of subjects: 161
Study 9758087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 9758087 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (cand.cil.) 8-16 mg o.i.d. for 12 weeks
Number of subjects: 161
Study 7522510 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) based chemotherapy or chemoimmunotherapy
Number of subjects: 136
Study 2978286 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) [alpha‐human ANF (99‐126)]
Number of subjects: 0
Study 2978286 — intervention group
Group type: COMPARATOR
Intervention: 0.9% (w/v) NaCl solution (saline)
Number of subjects: 0
Study 2978286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31859433 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA)
Number of subjects: 30
Study 31859433 — intervention group
Group type: COMPARATOR
Intervention: Sham-TEA
Number of subjects: 30
Study 29777953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous electrolysis
Number of subjects: 50
Study 29777953 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy and exercise
Number of subjects: 50
Study 29777953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 27998002 — intervention group
Group type: EXPERIMENTAL
Intervention: rBet v 1-FV allergen immunotherapy (AIT)
Number of subjects: 56
Study 27998002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 26852502 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ozone therapy
Number of subjects: 102
Study 26852502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of local and general ozone therapy
Number of subjects: 102
Study 26852502 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy alone
Number of subjects: 102
Study 23189931 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 170
Study 23189931 — intervention group
Group type: EXPERIMENTAL
Intervention: Supreme
Number of subjects: 170
Study 21514114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant with clamps opened at 120 seconds (FS-120; N = 24)
Number of subjects: 73
Study 21514114 — intervention group
Group type: COMPARATOR
Intervention: Manual compression with surgical gauze pads (control; N = 23)
Number of subjects: 73
Study 18496106 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Psychoeducation (SE)
Number of subjects: 249
Study 18496106 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Counseling (TC)
Number of subjects: 249
Study 18496106 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Psychoeducation plus Telephone Counseling (SE + TC)
Number of subjects: 249
Study 18496106 — intervention group
Group type: COMPARATOR
Intervention: Disease Management (DM)
Number of subjects: 249
Study 18496106 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 249
Study 16204324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 72
Study 16204324 — intervention group
Group type: COMPARATOR
Intervention: Balanced mixture (control)
Number of subjects: 72
Study 12952263 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-activating factor (PAF)
Number of subjects: 9
Study 12952263 — intervention group
Group type: COMPARATOR
Intervention: Lyso-PAF (L-PAF)
Number of subjects: 9
Study 10649811 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE), 0.625 mg/d
Number of subjects: 311
Study 10649811 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE), 1.25 mg/d
Number of subjects: 311
Study 10649811 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens, 0.625 mg + methyltestosterone, 1.25 mg/d
Number of subjects: 311
Study 10649811 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens, 1.25 mg + methyltestosterone, 2.5 mg/d
Number of subjects: 311
Study 10649811 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 311
Study 8886339 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate bar supplementation before exercise
Number of subjects: 16
Study 8886339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1986661 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 1 mg)
Number of subjects: 12
Study 1986661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6405056 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection followed by bladder instillations of thiotepa or VM‐26 (teniposide) for 1 year
Number of subjects: 308
Study 6405056 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 308
Study 29305927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (33.0 °C)
Number of subjects: 269
Study 29305927 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36.8 °C)
Number of subjects: 269
Study 29305927 — intervention group
Group type: EXPERIMENTAL
Intervention: VABS-II scores at 12 months
Number of subjects: 269
Study 29305927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive testing at 12 months
Number of subjects: 269
Study 29305927 — intervention group
Group type: EXPERIMENTAL
Intervention: VABS-II composite scores
Number of subjects: 269
Study 29305927 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of 3 and 12-month scores
Number of subjects: 269
Study 27514259 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention for 6 months through bulletin board, promotion materials, expert lecture, Q&A session, and other educational events.
Number of subjects: 990
Study 27514259 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention for 6 months.
Number of subjects: 990
Study 27514259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education).
Number of subjects: 990
Study 25040613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 50 mcg once-daily
Number of subjects: 351
Study 25040613 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 mcg twice-daily
Number of subjects: 351
Study 25040613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 22395779 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (75 mg intravenous)
Number of subjects: 248
Study 22395779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 20105234 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left DLPFC and cathodal tDCS over the right DLPFC
Number of subjects: 28
Study 20105234 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 28
Study 20105234 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal stimulation
Number of subjects: 28
Study 18192544 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin (12 units)
Number of subjects: 39
Study 18192544 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol plus AIR insulin (moderate asthma group only)
Number of subjects: 39
Study 18192544 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin lispro (12 units)
Number of subjects: 39
Study 16418159 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 1323
Study 16418159 — intervention group
Group type: COMPARATOR
Intervention: atomoxetine
Number of subjects: 1323
Study 12851613 — intervention group
Group type: EXPERIMENTAL
Intervention: roxifiban
Number of subjects: 31
Study 12851613 — intervention group
Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 31
Study 10323788 — intervention group
Group type: EXPERIMENTAL
Intervention: Used fat meal
Number of subjects: 12
Study 10323788 — intervention group
Group type: COMPARATOR
Intervention: Unused fat meal
Number of subjects: 12
Study 8611060 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment combined with weekly relapse prevention psychotherapy
Number of subjects: 69
Study 8611060 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 69
Study 8611060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 1934862 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 7
Study 1934862 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 7
Study 1934862 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg) with 300 ml water
Number of subjects: 7
Study 7073026 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoetharine (1% solution)
Number of subjects: 18
Study 7073026 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol (0.5% solution)
Number of subjects: 18
Study 6734291 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual screen with annual chest x-ray examination and four monthly sputum cytology evaluation
Number of subjects: 10040
Study 6734291 — intervention group
Group type: COMPARATOR
Intervention: Annual chest x-ray examinations only
Number of subjects: 10040
Study 29283207 — intervention group
Group type: EXPERIMENTAL
Intervention: Submerged healing group (n=14)
Number of subjects: 28
Study 29283207 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmucosal healing group (n=14)
Number of subjects: 28
Study 27484701 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg loading dose infused over 10 min followed by a constant infusion of 0.5 μg/kg/h) added to propofol-remifentanil regimen (DP adjusted group)
Number of subjects: 71
Study 27484701 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine added to propofol-remifentanil regimen without adjustment (DP unadjusted group)
Number of subjects: 71
Study 27484701 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil regimen (Propofol group)
Number of subjects: 71
Study 27484701 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg loading dose infused over 10 min followed by a constant infusion of 0.5 μg/kg/h) added to propofol-remifentanil regimen (DP unadjusted group)
Number of subjects: 71
Study 25522403 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan (160 mg daily for a minimum of 8 weeks)
Number of subjects: 17
Study 25522403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25522403 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan
Number of subjects: 17
Study 22460728 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic PPI use
Number of subjects: 30
Study 22460728 — intervention group
Group type: COMPARATOR
Intervention: Control group (never used antacid medications)
Number of subjects: 30
Study 20394460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist management of diabetes (including medication management, patient education, and disease control)
Number of subjects: 103
Study 20394460 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group management included registries and targeted patient outreach)
Number of subjects: 103
Study 20394460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist management of diabetes (specifically for nonwhite patients)
Number of subjects: 103
Study 20394460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist management of diabetes (specifically for male patients)
Number of subjects: 103
Study 17498718 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 9
Study 17498718 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 9
Study 17498718 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenols-stripped red wine
Number of subjects: 9
Study 17498718 — intervention group
Group type: COMPARATOR
Intervention: Ethanol-water solution
Number of subjects: 9
Study 17498718 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study 15976148 — intervention group
Group type: EXPERIMENTAL
Intervention: two servings of low energy-dense soup
Number of subjects: 200
Study 15976148 — intervention group
Group type: COMPARATOR
Intervention: comparison group (no special food)
Number of subjects: 200
Study 15976148 — intervention group
Group type: EXPERIMENTAL
Intervention: two servings of high energy-dense snack foods
Number of subjects: 200
Study 15976148 — intervention group
Group type: EXPERIMENTAL
Intervention: one serving of low energy-dense soup
Number of subjects: 200
Study 12055563 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 40
Study 12055563 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 10663352 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 120
Study 8739175 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun/Oral-B Plak Control (D7)
Number of subjects: 35
Study 8739175 — intervention group
Group type: COMPARATOR
Intervention: Sonicare (S)
Number of subjects: 35
Study 1756202 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP (0.5 mg/kg)
Number of subjects: 0
Study 1756202 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (480 mg)
Number of subjects: 0
Study 1756202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7042732 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 5 mg
Number of subjects: 40
Study 7042732 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg
Number of subjects: 40
Study 7042732 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 20 mg
Number of subjects: 40
Study 7042732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30428059 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Mutual-Group model (SMG) intervention for 7 months
Number of subjects: 350
Study 30428059 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 350
Study 28193257 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg/day to a maximum of 50 mg/day for 10 days
Number of subjects: 540
Study 28193257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (taste matched) for 10 days
Number of subjects: 540
Study 28193257 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 540
Study 25389300 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief TSP intervention
Number of subjects: 1101
Study 25389300 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 1101
Study 22528813 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated essential hypertension
Number of subjects: 60
Study 22528813 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control group
Number of subjects: 60
Study 22027927 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG/Dac (3 ATG, 2 Dac doses)
Number of subjects: 200
Study 22027927 — intervention group
Group type: COMPARATOR
Intervention: ATG/alemtuzumab (1 dose each)
Number of subjects: 200
Study 19928387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bright light pulses during night shifts, wearing dark sunglasses outside, scheduled sleep episodes in darkness
Number of subjects: 39
Study 19928387 — intervention group
Group type: COMPARATOR
Intervention: Control group with no interventions
Number of subjects: 39
Study 16827637 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-containing toothpaste (85 mg azithromycin per gram, prescribed b.i.d., 1.5 cm for 1 month)
Number of subjects: 20
Study 16827637 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-containing toothpaste
Number of subjects: 20
Study 16827637 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 20
Study 15018588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix (0.25mg daily injections or 3mg intermediate depot preparation)
Number of subjects: 0
Study 15018588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix (0.25mg daily injections)
Number of subjects: 0
Study 15018588 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist multiple-dose protocol
Number of subjects: 0
Study 15018588 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist single-dose protocol
Number of subjects: 0
Study 15018588 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist cycles
Number of subjects: 0
Study 11371127 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogs (leuprolide acetate) administered prior to and during polychemotherapy (PCT)
Number of subjects: 21
Study 11371127 — intervention group
Group type: COMPARATOR
Intervention: No GnRH analogs (Control Group A)
Number of subjects: 21
Study 11371127 — intervention group
Group type: COMPARATOR
Intervention: No GnRH analogs (Control Group C)
Number of subjects: 21
Study 9346996 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal screening for cystic fibrosis
Number of subjects: 0
Study 9346996 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic methods
Number of subjects: 0
Study 9346996 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group in urban center
Number of subjects: 0
Study 9346996 — intervention group
Group type: COMPARATOR
Intervention: Control group in other center
Number of subjects: 0
Study 9346996 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire CF populations in urban center
Number of subjects: 0
Study 8192646 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite index for treatment outcome research with social phobia
Number of subjects: 0
Study 8192646 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 0